| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: in general formula (I), X means CH 2 or C=O; R means hydrogen, Ar 1 , Ar 2 -Ar 3 , -(CH 2 ) q Ar 3 , -C(O)Ar 3 , C(O) - (CR x R y ) q -Ar 3 , -C(O) - (CR x R y ) q -O-Ar 3 or -C (O)-Ar 2 -AR 3 ; each of the fragments Ar 1 , Ar 2 and Ar 3 means C 6-10 aryl or 5-13-merous heteroaryl containing 1, 2 or 3 heteroatoms specified in N, O or S; q means 1, 2 or 3; R x and R y independently mean hydrogen or alkyl; wherein each aryl or heteroaryl are independently unsubstituted or substituted by 1, 2 or 3 substitutes specified in a group of alkyl, halogen, cyano, -OR 1a , -O-(CR 4a R 5a ) p -O-, -C(O)R 1a , -H(R b )(R 3a ), -H(R a )C(O)R 1a and halogenalkyl; wherein R 1a and R 3a independently mean hydrogen or alkyl; and R 4a and R 5a mean hydrogen; R a and R b independently mean hydrogen or alkyl; p means 1 or 2. n EFFECT: invention refers to the compounds of formula (I) possessing an activity modulating α7 nicotinic acetylcholine receptors, α4β2 nicotinic acetylcholine receptors or both subtypes of α7 and α4β2 nicotinic acetylcholine receptors, the based pharmaceutical composition and methods of treating with using them. n 18 cl, 1 tbl, 113 ex |